News
Day: February 19, 2025

According to Rupak De, Senior Technical Analyst at LKP Securities, the 22,800 level is expected to serve as a key support for the market. Unless this level is breached, a major downturn is unlikely. However, a decisive drop below 22,800 could trigger a significant correction. Until then, the market is expected to trade within a range. On the upside, Nifty may face resistance around 23,000-23,150, and a strong breakout above 23,150 could potentially drive a sharp rally.

India’s economic growth remains on track, supported by strong rural demand, recovering urban consumption, and positive fiscal measures from the Union Budget 2025-26. While global uncertainties and a strong US dollar present challenges, India’s robust domestic fundamentals—driven by government spending, tax relief, and a supportive monetary policy—are expected to propel the economy forward.

“The inspection, which commenced on 10 February 2025 and concluded on 18 February 2025, resulted in seven minor observations, none of which pertain to the data integrity of the facility,” the company said in a statement. As a result, Orchid Pharma continues to hold its exclusive position as India’s only USFDA-approved manufacturing site for sterile cephalosporins, it added.